CHELSEA THERAPEUTICS REPORTS CH-1594 DATA

A A

Chelsea Therapeutics has reported data from a Phase I trial of CH-1504, the company's lead product candidate in its portfolio of antifolate compounds.

The Phase I single- and multiple-ascending-dose trials of non-metabolized antifolate CH-1504 were conducted at Guy's Hospital in London in 2005. The trials were randomized, double-blind, placebo-controlled evaluations. The company added that the results from the trials suggested CH-1504 to be safe and well tolerated at all evaluated doses, with no clinically significant abnormalities observed.